[Weak antiviral effect of changing two nucleoside analogues combined with antiretroviral agents. 3TC and d4T after ZDU and ddi or ddc].
D
D
Rey
A C
AC
Schmitt
M P
MP
Schmitt
M
M
Partisani
M
M
Nicolle
G
G
Kempf-Durepaire
V
V
Krantz
J M
JM
Lang
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count / Q000187:drug effects; D016049:Didanosine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006679:HIV Seropositivity / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D012189:Retrospective Studies; D018119:Stavudine / Q000627:therapeutic use*; D019562:Viral Load; D016047:Zalcitabine / Q000627:therapeutic use*; D015215:Zidovudine / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D019259:Lamivudine; D015215:Zidovudine; D016047:Zalcitabine; D018119:Stavudine; D016049:Didanosine
Faible effet antiviral du changement de 2 analogues nucléosidiques dans une association d'antirétroviraux. 3TC + d4T en relais de ZDV + ddl ou ddC.